Absolute 0 8 0 8 B-clinical_variable
neutrophil 9 19 9 19 I-clinical_variable
count 20 25 20 25 I-clinical_variable
( 26 27 26 27 I-clinical_variable
ANC 27 30 27 30 I-clinical_variable
) 30 31 30 31 I-clinical_variable
> 32 33 32 33 O
1,000 34 39 34 39 B-lower_bound
/ 39 40 39 40 I-lower_bound
mm^3 40 44 40 44 I-lower_bound
or 45 47 45 47 O
> 48 49 48 49 O
500 50 53 50 53 B-lower_bound
/ 53 54 53 54 I-lower_bound
mm^3 54 58 54 58 I-lower_bound
if 59 61 59 61 O
neutropenia 62 73 62 73 B-chronic_disease
is 74 76 74 76 O
attributed 77 87 77 87 O
to 88 90 88 90 O
B 91 92 91 92 B-cancer
- 92 93 92 93 I-cancer
NHL 93 96 93 96 I-cancer
( 97 98 97 98 O
involvement 98 109 98 109 O
of 110 112 110 112 O
bone 113 117 113 117 O
marrow 118 124 118 124 O
) 124 125 124 125 O
without 126 133 126 133 O
growth 134 140 134 140 O
factor 141 147 141 147 O
support 148 155 148 155 O
and 156 159 156 159 O
platelet 160 168 160 168 B-clinical_variable
count 169 174 169 174 I-clinical_variable
> 175 176 175 176 O
100,000 177 184 177 184 B-lower_bound
/ 184 185 184 185 I-lower_bound
mm3 185 188 185 188 I-lower_bound
or 189 191 189 191 O
> 192 193 192 193 O
75,000 194 200 194 200 B-lower_bound
/ 200 201 200 201 I-lower_bound
mm^3 201 205 201 205 I-lower_bound
if 206 208 206 208 O
thrombocytopenia 209 225 209 225 B-chronic_disease
is 226 228 226 228 O
attributed 229 239 229 239 O
to 240 242 240 242 O
B 243 244 243 244 O
- 244 245 244 245 O
NHL 245 248 245 248 O
( 249 250 249 250 O
involvement 250 261 250 261 O
of 262 264 262 264 O
bone 265 269 265 269 O
marrow 270 276 270 276 O
or 277 279 277 279 O
due 280 283 280 283 O
to 284 286 284 286 O
splenomegaly 287 299 287 299 B-chronic_disease
or 300 302 300 302 O
immune 303 309 303 309 B-chronic_disease
thrombocytopenic 310 326 310 326 I-chronic_disease
purpura 327 334 327 334 I-chronic_disease
) 334 335 334 335 O

Agree 0 5 336 341 B-contraception_consent
to 6 8 342 344 I-contraception_consent
practice 9 17 345 353 I-contraception_consent
effective 18 27 354 363 I-contraception_consent
barrier 28 35 364 371 I-contraception_consent
contraception 36 49 372 385 I-contraception_consent
during 50 56 386 392 O
the 57 60 393 396 O
entire 61 67 397 403 O
study 68 73 404 409 B-treatment
treatment 74 83 410 419 I-treatment
period 84 90 420 426 O
and 91 94 427 430 O
through 95 102 431 438 O
90 103 105 439 441 B-upper_bound
days 106 110 442 446 I-upper_bound
after 111 116 447 452 O
the 117 120 453 456 O
last 121 125 457 461 O
dose 126 130 462 466 O
of 131 133 467 469 O
study 134 139 470 475 B-treatment
drug 140 144 476 480 I-treatment

Agree 0 5 481 486 B-contraception_consent
to 6 8 487 489 I-contraception_consent
practice 9 17 490 498 I-contraception_consent
true 18 22 499 503 I-contraception_consent
abstinence 23 33 504 514 I-contraception_consent
when 34 38 515 519 O
this 39 43 520 524 O
is 44 46 525 527 O
in 47 49 528 530 O
line 50 54 531 535 O
with 55 59 536 540 O
the 60 63 541 544 O
preferred 64 73 545 554 O
and 74 77 555 558 O
usual 78 83 559 564 O
lifestyle 84 93 565 574 O
of 94 96 575 577 O
the 97 100 578 581 O
subject 101 108 582 589 O

Alanine 0 7 590 597 B-clinical_variable
aminotransferase 8 24 598 614 I-clinical_variable
( 25 26 615 616 I-clinical_variable
ALT 26 29 616 619 I-clinical_variable
) 29 30 619 620 I-clinical_variable
and 31 34 621 624 I-clinical_variable
aspartate 35 44 625 634 I-clinical_variable
aminotransferase 45 61 635 651 I-clinical_variable
( 62 63 652 653 I-clinical_variable
AST 63 66 653 656 I-clinical_variable
) 66 67 656 657 I-clinical_variable
= 68 69 658 659 O
< 69 70 659 660 O
3 71 72 661 662 B-upper_bound
x 73 74 663 664 I-upper_bound
ULN 75 78 665 668 I-upper_bound

Any 0 3 669 672 O
serious 4 11 673 680 O
medical 12 19 681 688 O
or 20 22 689 691 O
psychiatric 23 34 692 703 B-chronic_disease
illness 35 42 704 711 I-chronic_disease
that 43 47 712 716 O
could 48 53 717 722 O
, 53 54 722 723 O
in 55 57 724 726 O
the 58 61 727 730 O
investigator 62 74 731 743 O
's 74 76 743 745 O
opinion 77 84 746 753 O
, 84 85 753 754 O
potentially 86 97 755 766 O
interfere 98 107 767 776 O
with 108 112 777 781 O
the 113 116 782 785 O
completion 117 127 786 796 O
of 128 130 797 799 O
treatment 131 140 800 809 B-treatment
according 141 150 810 819 O
to 151 153 820 822 O
this 154 158 823 827 O
protocol 159 167 828 836 O

Are 0 3 837 840 O
postmenopausal 4 18 841 855 O
for 19 22 856 859 O
at 23 25 860 862 O
least 26 31 863 868 O
1 32 33 869 870 B-lower_bound
year 34 38 871 875 I-lower_bound
before 39 45 876 882 O
the 46 49 883 886 O
screening 50 59 887 896 O
visit 60 65 897 902 O

Calculated 0 10 903 913 B-clinical_variable
creatinine 11 21 914 924 I-clinical_variable
clearance 22 31 925 934 I-clinical_variable
> 32 33 935 936 O
= 33 34 936 937 O
30 35 37 938 940 B-lower_bound
mL 38 40 941 943 I-lower_bound
/ 40 41 943 944 I-lower_bound
min 41 44 944 947 I-lower_bound

Diagnosed 0 9 948 957 O
or 10 12 958 960 O
treated 13 20 961 968 O
for 21 24 969 972 O
another 25 32 973 980 O
malignancy 33 43 981 991 B-cancer
within 44 50 992 998 O
2 51 52 999 1000 B-lower_bound
years 53 58 1001 1006 I-lower_bound
before 59 65 1007 1013 I-upper_bound
study 66 71 1014 1019 O
enrollment 72 82 1020 1030 O
or 83 85 1031 1033 O
previously 86 96 1034 1044 O
diagnosed 97 106 1045 1054 O
( 107 108 1055 1056 O
> 108 109 1056 1057 O
2 110 111 1058 1059 O
years 112 117 1060 1065 O
before 118 124 1066 1072 O
study 125 130 1073 1078 O
enrollment 131 141 1079 1089 O
) 141 142 1089 1090 O
with 143 147 1091 1095 O
another 148 155 1096 1103 O
malignancy 156 166 1104 1114 O
and 167 170 1115 1118 O
have 171 175 1119 1123 O
any 176 179 1124 1127 O
evidence 180 188 1128 1136 O
of 189 191 1137 1139 O
residual 192 200 1140 1148 B-cancer
disease 201 208 1149 1156 I-cancer
that 209 213 1157 1161 O
is 214 216 1162 1164 O
symptomatic 217 228 1165 1176 O
or 229 231 1177 1179 O
requiring 232 241 1180 1189 O
treatment 242 251 1190 1199 B-treatment

Disease 0 7 1200 1207 O
: 7 8 1207 1208 O
CLL 9 12 1209 1212 B-cancer
/ 12 13 1212 1213 O
SLL 13 16 1213 1216 B-cancer
; 16 17 1216 1217 O
Criteria 18 26 1218 1226 O
for 27 30 1227 1230 O
diagnosis 31 40 1231 1240 O
: 40 41 1240 1241 O
histopathologic 42 57 1242 1257 O
or 58 60 1258 1260 O
flow 61 65 1261 1265 O
cytometric 66 76 1266 1276 O
confirmation 77 89 1277 1289 O

Disease 0 7 1290 1297 O
: 7 8 1297 1298 O
FL 9 11 1299 1301 B-cancer
; 11 12 1301 1302 O
Criteria 13 21 1303 1311 O
for 22 25 1312 1315 O
diagnosis 26 35 1316 1325 O
: 35 36 1325 1326 O
histopathologic 37 52 1327 1342 O
confirmation 53 65 1343 1355 O

Disease 0 7 1356 1363 O
: 7 8 1363 1364 O
MCL 9 12 1365 1368 B-cancer
; 12 13 1368 1369 O
Criteria 14 22 1370 1378 O
for 23 26 1379 1382 O
diagnosis 27 36 1383 1392 O
: 36 37 1392 1393 O
histopathologic 38 53 1394 1409 O
confirmation 54 66 1410 1422 O

Disease 0 7 1423 1430 O
: 7 8 1430 1431 O
MZL 9 12 1432 1435 B-cancer
; 12 13 1435 1436 O
Criteria 14 22 1437 1445 O
for 23 26 1446 1449 O
diagnosis 27 36 1450 1459 O
: 36 37 1459 1460 O
histopathologic 38 53 1461 1476 O
confirmation 54 66 1477 1489 O

Disease 0 7 1490 1497 O
: 7 8 1497 1498 O
WM 9 11 1499 1501 B-cancer
/ 11 12 1501 1502 O
LPL 12 15 1502 1505 B-cancer
; 15 16 1505 1506 O
Criteria 17 25 1507 1515 O
for 26 29 1516 1519 O
diagnosis 30 39 1520 1529 O
: 39 40 1529 1530 O
Per 41 44 1531 1534 O
World 45 50 1535 1540 O
Health 51 57 1541 1547 O
Organization 58 70 1548 1560 O
( 71 72 1561 1562 O
WHO 72 75 1562 1565 O
) 75 76 1565 1566 O
criteria 77 85 1567 1575 O

Eastern 0 7 1576 1583 B-clinical_variable
Cooperative 8 19 1584 1595 I-clinical_variable
Oncology 20 28 1596 1604 I-clinical_variable
Group 29 34 1605 1610 I-clinical_variable
( 35 36 1611 1612 I-clinical_variable
ECOG 36 40 1612 1616 I-clinical_variable
) 40 41 1616 1617 I-clinical_variable
performance 42 53 1618 1629 I-clinical_variable
status 54 60 1630 1636 I-clinical_variable
and/or 61 67 1637 1643 O
other 68 73 1644 1649 O
performance 74 85 1650 1661 O
status 86 92 1662 1668 O
0 93 94 1669 1670 B-lower_bound
, 94 95 1670 1671 O
1 96 97 1672 1673 O
, 97 98 1673 1674 O
or 99 101 1675 1677 O
2 102 103 1678 1679 B-upper_bound

Evidence 0 8 1680 1688 O
of 9 11 1689 1691 O
current 12 19 1692 1699 O
uncontrolled 20 32 1700 1712 O
cardiovascular 33 47 1713 1727 B-chronic_disease
conditions 48 58 1728 1738 I-chronic_disease
, 58 59 1738 1739 O
including 60 69 1740 1749 O
uncontrolled 70 82 1750 1762 O
hypertension 83 95 1763 1775 B-chronic_disease
, 95 96 1775 1776 O
cardiac 97 104 1777 1784 B-chronic_disease
arrhythmias 105 116 1785 1796 I-chronic_disease
, 116 117 1796 1797 O
or 118 120 1798 1800 O
congestive 121 131 1801 1811 B-chronic_disease
heart 132 137 1812 1817 I-chronic_disease
failure 138 145 1818 1825 I-chronic_disease
, 145 146 1825 1826 O
and 147 150 1827 1830 O
unstable 151 159 1831 1839 B-chronic_disease
angina 160 166 1840 1846 I-chronic_disease
or 167 169 1847 1849 O
myocardial 170 180 1850 1860 B-chronic_disease
infarction 181 191 1861 1871 I-chronic_disease
within 192 198 1872 1878 O
the 199 202 1879 1882 O
past 203 207 1883 1887 B-upper_bound
6 208 209 1888 1889 I-upper_bound
months 210 216 1890 1896 I-upper_bound

Female 0 6 1897 1903 B-gender
patients 7 15 1904 1912 I-gender

Female 0 6 1913 1919 B-gender
patients 7 15 1920 1928 I-gender
who 16 19 1929 1932 O
are 20 23 1933 1936 O
lactating 24 33 1937 1946 O
or 34 36 1947 1949 O
have 37 41 1950 1954 O
a 42 43 1955 1956 O
positive 44 52 1957 1965 B-pregnancy
serum 53 58 1966 1971 I-pregnancy
pregnancy 59 68 1972 1981 I-pregnancy
test 69 73 1982 1986 O
during 74 80 1987 1993 O
the 81 84 1994 1997 O
screening 85 94 1998 2007 O
period 95 101 2008 2014 O

In 0 2 2015 2017 O
patients 3 11 2018 2026 O
with 12 16 2027 2031 O
CLL 17 20 2032 2035 B-cancer
, 20 21 2035 2036 O
circulating 22 33 2037 2048 O
lymphocytes 34 45 2049 2060 B-clinical_variable
> 46 47 2061 2062 O
= 47 48 2062 2063 O
5,000 49 54 2064 2069 B-lower_bound
/ 55 56 2070 2071 I-lower_bound
mm^3 57 61 2072 2076 I-lower_bound

In 0 2 2077 2079 O
patients 3 11 2080 2088 O
with 12 16 2089 2093 O
WM 17 19 2094 2096 B-cancer
/ 19 20 2096 2097 O
LPL 20 23 2097 2100 B-cancer
, 23 24 2100 2101 O
measurable 25 35 2102 2112 O
serum 36 41 2113 2118 O
monoclonal 42 52 2119 2129 O
immunoglobulin 53 67 2130 2144 O
M 68 69 2145 2146 O
( 70 71 2147 2148 O
IgM 71 74 2148 2151 O
) 74 75 2151 2152 O

Infection 0 9 2153 2162 B-chronic_disease
requiring 10 19 2163 2172 O
systemic 20 28 2173 2181 B-treatment
antibiotic 29 39 2182 2192 I-treatment
therapy 40 47 2193 2200 I-treatment
or 48 50 2201 2203 O
other 51 56 2204 2209 O
serious 57 64 2210 2217 O
infection 65 74 2218 2227 B-chronic_disease
within 75 81 2228 2234 O
14 82 84 2235 2237 B-upper_bound
days 85 89 2238 2242 I-upper_bound
before 90 96 2243 2249 I-upper_bound
study 97 102 2250 2255 O
enrollment 103 113 2256 2266 O

Known 0 5 2267 2272 O
allergy 6 13 2273 2280 O
to 14 16 2281 2283 O
ixazomib 17 25 2284 2292 B-allergy_name
, 25 26 2292 2293 O
its 27 30 2294 2297 O
analogues 31 40 2298 2307 O
, 40 41 2307 2308 O
or 42 44 2309 2311 O
excipients 45 55 2312 2322 O
in 56 58 2323 2325 O
the 59 62 2326 2329 O
various 63 70 2330 2337 O
formulations 71 83 2338 2350 O
of 84 86 2351 2353 O
ixazomib 87 95 2354 2362 O

Known 0 5 2363 2368 O
gastrointestinal 6 22 2369 2385 B-chronic_disease
( 23 24 2386 2387 I-chronic_disease
GI 24 26 2387 2389 I-chronic_disease
) 26 27 2389 2390 I-chronic_disease
disease 28 35 2391 2398 I-chronic_disease
or 36 38 2399 2401 O
GI 39 41 2402 2404 B-treatment
procedure 42 51 2405 2414 I-treatment
that 52 56 2415 2419 O
could 57 62 2420 2425 O
interfere 63 72 2426 2435 O
with 73 77 2436 2440 O
the 78 81 2441 2444 O
oral 82 86 2445 2449 O
absorption 87 97 2450 2460 O
or 98 100 2461 2463 O
tolerance 101 110 2464 2473 O
of 111 113 2474 2476 O
ixazomib 114 122 2477 2485 B-treatment
including 123 132 2486 2495 O
difficulty 133 143 2496 2506 O
swallowing 144 154 2507 2517 O

Known 0 5 2518 2523 O
ongoing 6 13 2524 2531 O
or 14 16 2532 2534 O
known 17 22 2535 2540 O
active 23 29 2541 2547 O
systemic 30 38 2548 2556 B-chronic_disease
infection 39 48 2557 2566 I-chronic_disease
, 48 49 2566 2567 O
known 50 55 2568 2573 O
active 56 62 2574 2580 O
hepatitis 63 72 2581 2590 B-chronic_disease
B 73 74 2591 2592 I-chronic_disease
or 75 77 2593 2595 O
C 78 79 2596 2597 B-chronic_disease
virus 80 85 2598 2603 B-chronic_disease
infection 86 95 2604 2613 I-chronic_disease
, 95 96 2613 2614 O
or 97 99 2615 2617 O
known 100 105 2618 2623 O
human 106 111 2624 2629 B-chronic_disease
immunodeficiency 112 128 2630 2646 I-chronic_disease
virus 129 134 2647 2652 I-chronic_disease
( 135 136 2653 2654 I-chronic_disease
HIV 136 139 2654 2657 I-chronic_disease
) 139 140 2657 2658 I-chronic_disease
positive 141 149 2659 2667 O

Lesions 0 7 2668 2675 B-clinical_variable
greater 8 15 2676 2683 O
than 16 20 2684 2688 O
1.5 21 24 2689 2692 B-lower_bound
cm 25 27 2693 2695 I-lower_bound
that 28 32 2696 2700 O
can 33 36 2701 2704 O
be 37 39 2705 2707 O
accurately 40 50 2708 2718 O
measured 51 59 2719 2727 O
in 60 62 2728 2730 O
two 63 66 2731 2734 O
dimensions 67 77 2735 2745 O
by 78 80 2746 2748 O
computed 81 89 2749 2757 B-treatment
tomography 90 100 2758 2768 I-treatment
( 101 102 2769 2770 I-treatment
CT 102 104 2770 2772 I-treatment
) 104 105 2772 2773 I-treatment
( 106 107 2774 2775 O
preferred 107 116 2775 2784 O
) 116 117 2784 2785 O
, 117 118 2785 2786 O
or 119 121 2787 2789 O
magnetic 122 130 2790 2798 B-treatment
resonance 131 140 2799 2808 I-treatment
imaging 141 148 2809 2816 I-treatment
( 149 150 2817 2818 I-treatment
MRI 150 153 2818 2821 I-treatment
) 153 154 2821 2822 I-treatment
, 154 155 2822 2823 O
and 156 159 2824 2827 O
are 160 163 2828 2831 O
not 164 167 2832 2835 O
included 168 176 2836 2844 O
in 177 179 2845 2847 O
any 180 183 2848 2851 O
prior 184 189 2852 2857 B-treatment
field 190 195 2858 2863 I-treatment
of 196 198 2864 2866 I-treatment
radiation 199 208 2867 2876 I-treatment
given 209 214 2877 2882 O
to 215 217 2883 2885 O
treat 218 223 2886 2891 O
B 224 225 2892 2893 B-cancer
- 225 226 2893 2894 I-cancer
NHL 226 229 2894 2897 I-cancer

Major 0 5 2898 2903 B-treatment
surgery 6 13 2904 2911 I-treatment
within 14 20 2912 2918 O
14 21 23 2919 2921 B-upper_bound
days 24 28 2922 2926 I-upper_bound
before 29 35 2927 2933 O
enrollment 36 46 2934 2944 O

Male 0 4 2945 2949 B-gender
patients 5 13 2950 2958 I-gender
, 13 14 2958 2959 O
even 15 19 2960 2964 O
if 20 22 2965 2967 O
surgically 23 33 2968 2978 O
sterilized 34 44 2979 2989 O
( 45 46 2990 2991 O
i.e. 46 50 2991 2995 O
, 50 51 2995 2996 O
status 52 58 2997 3003 O
post 59 63 3004 3008 O
- 63 64 3008 3009 O
vasectomy 64 73 3009 3018 B-treatment
) 73 74 3018 3019 O
, 74 75 3019 3020 O
must 76 80 3021 3025 O
agree 81 86 3026 3031 O
to 87 89 3032 3034 O
one 90 93 3035 3038 O
of 94 96 3039 3041 O
the 97 100 3042 3045 O
following 101 110 3046 3055 O

Participation 0 13 3056 3069 O
in 14 16 3070 3072 O
other 17 22 3073 3078 O
clinical 23 31 3079 3087 O
trials 32 38 3088 3094 O
with 39 43 3095 3099 O
other 44 49 3100 3105 O
investigational 50 65 3106 3121 B-treatment
agents 66 72 3122 3128 I-treatment
not 73 76 3129 3132 O
included 77 85 3133 3141 O
in 86 88 3142 3144 O
this 89 93 3145 3149 O
trial 94 99 3150 3155 O
, 99 100 3155 3156 O
within 101 107 3157 3163 O
21 108 110 3164 3166 B-upper_bound
days 111 115 3167 3171 I-upper_bound
of 116 118 3172 3174 O
the 119 122 3175 3178 O
start 123 128 3179 3184 O
of 129 131 3185 3187 O
this 132 136 3188 3192 O
trial 137 142 3193 3198 O
and 143 146 3199 3202 O
throughout 147 157 3203 3213 O
the 158 161 3214 3217 O
duration 162 170 3218 3226 O
of 171 173 3227 3229 O
this 174 178 3230 3234 O
trial 179 184 3235 3240 O

Patient 0 7 3241 3248 O
has 8 11 3249 3252 O
> 12 13 3253 3254 O
= 13 14 3254 3255 O
grade 15 20 3256 3261 B-lower_bound
2 21 22 3262 3263 I-lower_bound
peripheral 23 33 3264 3274 B-clinical_variable
neuropathy 34 44 3275 3285 I-clinical_variable
, 44 45 3285 3286 O
or 46 48 3287 3289 O
grade 49 54 3290 3295 O
1 55 56 3296 3297 O
with 57 61 3298 3302 O
pain 62 66 3303 3307 O
on 67 69 3308 3310 O
clinical 70 78 3311 3319 B-treatment
examination 79 90 3320 3331 I-treatment
during 91 97 3332 3338 O
the 98 101 3339 3342 O
screening 102 111 3343 3352 O
period 112 118 3353 3359 O

Patients 0 8 3360 3368 O
are 9 12 3369 3372 O
required 13 21 3373 3381 O
to 22 24 3382 3384 O
meet 25 29 3385 3389 O
criteria 30 38 3390 3398 O
for 39 42 3399 3402 O
initiation 43 53 3403 3413 O
of 54 56 3414 3416 O
therapy 57 64 3417 3424 B-treatment
for 65 68 3425 3428 O
their 69 74 3429 3434 O
B 75 76 3435 3436 B-cancer
- 76 77 3436 3437 I-cancer
NHL 77 80 3437 3440 I-cancer
according 81 90 3441 3450 O
to 91 93 3451 3453 O
published 94 103 3454 3463 O
guidelines 104 114 3464 3474 O
by 115 117 3475 3477 O
the 118 121 3478 3481 O
National 122 130 3482 3490 O
Comprehensive 131 144 3491 3504 O
Cancer 145 151 3505 3511 O
Network 152 159 3512 3519 O
( 160 161 3520 3521 O
NCCN 161 165 3521 3525 O
) 165 166 3525 3526 O

Patients 0 8 3527 3535 O
must 9 13 3536 3540 O
have 14 18 3541 3545 O
a 19 20 3546 3547 O
diagnosis 21 30 3548 3557 O
of 31 33 3558 3560 O
one 34 37 3561 3564 O
of 38 40 3565 3567 O
the 41 44 3568 3571 O
following 45 54 3572 3581 O
B 55 56 3582 3583 B-cancer
- 56 57 3583 3584 I-cancer
NHL 57 60 3584 3587 I-cancer
malignancies 61 73 3588 3600 I-cancer

Patients 0 8 3601 3609 O
must 9 13 3610 3614 O
have 14 18 3615 3619 O
measurable 19 29 3620 3630 O
disease 30 37 3631 3638 O
defined 38 45 3639 3646 O
by 46 48 3647 3649 O
at 49 51 3650 3652 O
least 52 57 3653 3658 O
one 58 61 3659 3662 B-lower_bound
of 62 64 3663 3665 O
the 65 68 3666 3669 O
following 69 78 3670 3679 O
criteria 79 87 3680 3688 O

Prior 0 5 3689 3694 B-treatment
treatment 6 15 3695 3704 I-treatment
of 16 18 3705 3707 O
B 19 20 3708 3709 B-cancer
- 20 21 3709 3710 I-cancer
NHL 21 24 3710 3713 I-cancer
with 25 29 3714 3718 O
radiation 30 39 3719 3728 B-treatment
therapy 40 47 3729 3736 I-treatment
, 47 48 3736 3737 O
non 49 52 3738 3741 B-treatment
- 52 53 3741 3742 I-treatment
standard 53 61 3742 3750 I-treatment
systemic 62 70 3751 3759 I-treatment
therapy 71 78 3760 3767 I-treatment
, 78 79 3767 3768 O
or 80 82 3769 3771 O
antibiotics 83 94 3772 3783 B-treatment
( 95 96 3784 3785 O
in 96 98 3785 3787 O
cases 99 104 3788 3793 O
of 105 107 3794 3796 O
MZL 108 111 3797 3800 B-cancer
) 111 112 3800 3801 O
within 113 119 3802 3808 O
21 120 122 3809 3811 B-upper_bound
days 123 127 3812 3816 I-upper_bound
of 128 130 3817 3819 O
the 131 134 3820 3823 O
first 135 140 3824 3829 O
dose 141 145 3830 3834 O
of 146 148 3835 3837 O
ixazomib 149 157 3838 3846 B-treatment

Systemic 0 8 3847 3855 B-treatment
treatment 9 18 3856 3865 I-treatment
, 18 19 3865 3866 O
within 20 26 3867 3873 O
14 27 29 3874 3876 B-upper_bound
days 30 34 3877 3881 I-upper_bound
before 35 41 3882 3888 I-upper_bound
the 42 45 3889 3892 O
first 46 51 3893 3898 O
dose 52 56 3899 3903 O
of 57 59 3904 3906 O
ixazomib 60 68 3907 3915 B-treatment
, 68 69 3915 3916 O
with 70 74 3917 3921 O
strong 75 81 3922 3928 B-treatment
inhibitors 82 92 3929 3939 I-treatment
of 93 95 3940 3942 I-treatment
cytochrome 96 106 3943 3953 I-treatment
P450 107 111 3954 3958 I-treatment
, 111 112 3958 3959 O
family 113 119 3960 3966 O
1 120 121 3967 3968 O
, 121 122 3968 3969 O
subfamily 123 132 3970 3979 O
A 133 134 3980 3981 O
, 134 135 3981 3982 O
polypeptide 136 147 3983 3994 B-treatment
2 148 149 3995 3996 I-treatment
( 150 151 3997 3998 I-treatment
CYP1A2 151 157 3998 4004 I-treatment
) 157 158 4004 4005 I-treatment
( 159 160 4006 4007 O
fluvoxamine 160 171 4007 4018 B-treatment
, 171 172 4018 4019 O
enoxacin 173 181 4020 4028 B-treatment
, 181 182 4028 4029 O
ciprofloxacin 183 196 4030 4043 B-treatment
) 196 197 4043 4044 O
, 197 198 4044 4045 O
strong 199 205 4046 4052 O
inhibitors 206 216 4053 4063 O
of 217 219 4064 4066 O
cytochrome 220 230 4067 4077 O
P450 231 235 4078 4082 O
, 235 236 4082 4083 O
family 237 243 4084 4090 O
3 244 245 4091 4092 O
, 245 246 4092 4093 O
subfamily 247 256 4094 4103 O
A 257 258 4104 4105 O
( 259 260 4106 4107 O
CYP3A 260 265 4107 4112 B-treatment
) 265 266 4112 4113 O
( 267 268 4114 4115 O
clarithromycin 268 282 4115 4129 B-treatment
, 282 283 4129 4130 O
telithromycin 284 297 4131 4144 B-treatment
, 297 298 4144 4145 O
itraconazole 299 311 4146 4158 B-treatment
, 311 312 4158 4159 O
voriconazole 313 325 4160 4172 B-treatment
, 325 326 4172 4173 O
ketoconazole 327 339 4174 4186 B-treatment
, 339 340 4186 4187 O
nefazodone 341 351 4188 4198 B-treatment
, 351 352 4198 4199 O
posaconazole 353 365 4200 4212 B-treatment
) 365 366 4212 4213 O
or 367 369 4214 4216 O
strong 370 376 4217 4223 B-treatment
CYP3A 377 382 4224 4229 I-treatment
inducers 383 391 4230 4238 I-treatment
( 392 393 4239 4240 O
rifampin 393 401 4240 4248 B-treatment
, 401 402 4248 4249 O
rifapentine 403 414 4250 4261 B-treatment
, 414 415 4261 4262 O
rifabutin 416 425 4263 4272 B-treatment
, 425 426 4272 4273 O
carbamazepine 427 440 4274 4287 B-treatment
, 440 441 4287 4288 O
phenytoin 442 451 4289 4298 B-treatment
, 451 452 4298 4299 O
phenobarbital 453 466 4300 4313 B-treatment
) 466 467 4313 4314 O
, 467 468 4314 4315 O
or 469 471 4316 4318 O
use 472 475 4319 4322 O
of 476 478 4323 4325 O
ginkgo 479 485 4326 4332 B-treatment
biloba 486 492 4333 4339 I-treatment
or 493 495 4340 4342 O
St. 496 499 4343 4346 B-treatment
John 500 504 4347 4351 I-treatment
's 504 506 4351 4353 I-treatment
wort 507 511 4354 4358 I-treatment

Total 0 5 4359 4364 B-clinical_variable
bilirubin 6 15 4365 4374 I-clinical_variable
= 16 17 4375 4376 O
< 17 18 4376 4377 O
1.5 18 21 4377 4380 B-upper_bound
x 22 23 4381 4382 I-upper_bound
the 24 27 4383 4386 I-upper_bound
upper 28 33 4387 4392 I-upper_bound
limit 34 39 4393 4398 I-upper_bound
of 40 42 4399 4401 I-upper_bound
the 43 46 4402 4405 I-upper_bound
normal 47 53 4406 4412 I-upper_bound
range 54 59 4413 4418 I-upper_bound
( 60 61 4419 4420 I-upper_bound
ULN 61 64 4420 4423 I-upper_bound
) 64 65 4423 4424 I-upper_bound

anti 0 4 4425 4429 B-treatment
- 4 5 4429 4430 I-treatment
CD20 5 9 4430 4434 I-treatment
antibodies 10 20 4435 4445 I-treatment
( 21 22 4446 4447 O
obinutuzumab 22 34 4447 4459 B-treatment
, 34 35 4459 4460 O
ofatumumab 36 46 4461 4471 B-treatment
, 46 47 4471 4472 O
rituximab 48 57 4473 4482 B-treatment
) 57 58 4482 4483 O
; 58 59 4483 4484 O
lenalidomide 60 72 4485 4497 B-treatment
; 72 73 4497 4498 O
ibritumomab 74 85 4499 4510 B-treatment
tiuxetan 86 94 4511 4519 I-treatment
; 94 95 4519 4520 O
proteasome 96 106 4521 4531 B-treatment
inhibitors 107 117 4532 4542 I-treatment
( 118 119 4543 4544 O
bortezomib 119 129 4544 4554 B-treatment
, 129 130 4554 4555 O
carfilzomib 131 142 4556 4567 B-treatment
) 142 143 4567 4568 O
; 143 144 4568 4569 O
tyrosine 145 153 4570 4578 B-treatment
kinase 154 160 4579 4585 I-treatment
inhibitors 161 171 4586 4596 I-treatment
( 172 173 4597 4598 O
ibrutinib 173 182 4598 4607 B-treatment
, 182 183 4607 4608 O
acalabrutinib 184 197 4609 4622 B-treatment
, 197 198 4622 4623 O
idelalisib 199 209 4624 4634 B-treatment
) 209 210 4634 4635 O
; 210 211 4635 4636 O
alemtuzumab 212 223 4637 4648 B-treatment
; 223 224 4648 4649 O
corticosteroids 225 240 4650 4665 B-treatment
unless 241 247 4666 4672 O
given 248 253 4673 4678 O
for 254 257 4679 4682 O
an 258 260 4683 4685 O
indication 261 271 4686 4696 O
other 272 277 4697 4702 O
than 278 282 4703 4707 O
treating 283 291 4708 4716 O
the 292 295 4717 4720 O
B 296 297 4721 4722 B-cancer
- 297 298 4722 4723 I-cancer
NHL 298 301 4723 4726 I-cancer

chronic 0 7 4727 4734 B-cancer
lymphocytic 8 19 4735 4746 I-cancer
leukemia 20 28 4747 4755 I-cancer
( 29 30 4756 4757 I-cancer
CLL)/ 30 35 4757 4762 I-cancer
small 36 41 4763 4768 B-cancer
lymphocytic 42 53 4769 4780 I-cancer
lymphoma 54 62 4781 4789 I-cancer
( 63 64 4790 4791 I-cancer
SLL 64 67 4791 4794 I-cancer
) 67 68 4794 4795 I-cancer
, 68 69 4795 4796 O
follicular 70 80 4797 4807 B-cancer
lymphoma 81 89 4808 4816 I-cancer
( 90 91 4817 4818 I-cancer
FL 91 93 4818 4820 I-cancer
) 93 94 4820 4821 I-cancer
, 94 95 4821 4822 O
mantle 96 102 4823 4829 B-cancer
cell 103 107 4830 4834 I-cancer
lymphoma 108 116 4835 4843 I-cancer
( 117 118 4844 4845 I-cancer
MCL 118 121 4845 4848 I-cancer
) 121 122 4848 4849 I-cancer
, 122 123 4849 4850 O
marginal 124 132 4851 4859 B-cancer
zone 133 137 4860 4864 I-cancer
lymphoma 138 146 4865 4873 I-cancer
( 147 148 4874 4875 I-cancer
MZL 148 151 4875 4878 I-cancer
) 151 152 4878 4879 I-cancer
, 152 153 4879 4880 O
or 154 156 4881 4883 O
Waldenstrom 157 168 4884 4895 B-cancer
macroglobulinemia 169 186 4896 4913 I-cancer
( 187 188 4914 4915 I-cancer
WM)/ 188 192 4915 4919 I-cancer
lymphoplasmacytic 193 210 4920 4937 B-cancer
lymphoma 211 219 4938 4946 I-cancer
( 220 221 4947 4948 I-cancer
LPL 221 224 4948 4951 I-cancer
) 224 225 4951 4952 I-cancer

other 0 5 4953 4958 O
therapy 6 13 4959 4966 B-treatment
as 14 16 4967 4969 O
determined 17 27 4970 4980 O
by 28 30 4981 4983 O
the 31 34 4984 4987 O
principal 35 44 4988 4997 O
investigator 45 57 4998 5010 O
( 58 59 5011 5012 O
PI 59 61 5012 5014 O
) 61 62 5014 5015 O

otherwise 0 9 5016 5025 O
, 9 10 5025 5026 O
patients 11 19 5027 5035 O
will 20 24 5036 5040 O
not 25 28 5041 5044 O
have 29 33 5045 5049 O
received 34 42 5050 5058 O
standard 43 51 5059 5067 O
systemic 52 60 5068 5076 B-treatment
treatment 61 70 5077 5086 I-treatment
for 71 74 5087 5090 O
their 75 80 5091 5096 O
B 81 82 5097 5098 O
- 82 83 5098 5099 O
NHL 83 86 5099 5102 O
before 87 93 5103 5109 O
the 94 97 5110 5113 O
time 98 102 5114 5118 O
of 103 105 5119 5121 O
study 106 111 5122 5127 O
enrollment 112 122 5128 5138 O

patients 0 8 5139 5147 O
with 9 13 5148 5152 O
mucosa 14 20 5153 5159 B-chronic_disease
associated 21 31 5160 5170 I-chronic_disease
lymphoid 32 40 5171 5179 I-chronic_disease
tissue 41 47 5180 5186 I-chronic_disease
( 48 49 5187 5188 I-chronic_disease
MALT 49 53 5188 5192 I-chronic_disease
) 53 54 5192 5193 I-chronic_disease
subtype 55 62 5194 5201 O
of 63 65 5202 5204 O
MZL 66 69 5205 5208 O
may 70 73 5209 5212 O
have 74 78 5213 5217 O
relapsed 79 87 5218 5226 O
or 88 90 5227 5229 O
refractory 91 101 5230 5240 O
disease 102 109 5241 5248 O
after 110 115 5249 5254 O
a 116 117 5255 5256 O
course 118 124 5257 5263 O
of 125 127 5264 5266 O
antibiotic 128 138 5267 5277 B-treatment
therapy 139 146 5278 5285 I-treatment

platelet 0 8 5286 5294 B-treatment
transfusions 9 21 5295 5307 I-treatment
to 22 24 5308 5310 O
help 25 29 5311 5315 O
patients 30 38 5316 5324 O
meet 39 43 5325 5329 O
eligibility 44 55 5330 5341 O
criteria 56 64 5342 5350 O
are 65 68 5351 5354 O
not 69 72 5355 5358 O
allowed 73 80 5359 5366 O
within 81 87 5367 5373 O
3 88 89 5374 5375 B-upper_bound
days 90 94 5376 5380 I-upper_bound
before 95 101 5381 5387 I-upper_bound
study 102 107 5388 5393 O
enrollment 108 118 5394 5404 O

standard 0 8 5405 5413 B-treatment
systemic 9 17 5414 5422 I-treatment
therapy 18 25 5423 5430 I-treatment
is 26 28 5431 5433 O
defined 29 36 5434 5441 O
by 37 39 5442 5444 O
including 40 49 5445 5454 O
any 50 53 5455 5458 O
of 54 56 5459 5461 O
the 57 60 5462 5465 O
following 61 70 5466 5475 O
agents 71 77 5476 5482 O
, 77 78 5482 5483 O
representing 79 91 5484 5496 O
a 92 93 5497 5498 O
comprehensive 94 107 5499 5512 O
list 108 112 5513 5517 O
of 113 115 5518 5520 O
recommended 116 127 5521 5532 O
front 128 133 5533 5538 B-treatment
- 133 134 5538 5539 I-treatment
line 134 138 5539 5543 I-treatment
agents 139 145 5544 5550 I-treatment
used 146 150 5551 5555 O
in 151 153 5556 5558 O
the 154 157 5559 5562 O
treatment 158 167 5563 5572 B-treatment
of 168 170 5573 5575 O
B 171 172 5576 5577 B-cancer
- 172 173 5577 5578 I-cancer
NHL 173 176 5578 5581 I-cancer
: 176 177 5581 5582 O
cytotoxic 178 187 5583 5592 B-treatment
chemotherapies 188 202 5593 5607 I-treatment
( 203 204 5608 5609 O
bendamustine 204 216 5609 5621 B-treatment
, 216 217 5621 5622 O
cyclophosphamide 218 234 5623 5639 B-treatment
, 234 235 5639 5640 O
doxorubicin 236 247 5641 5652 B-treatment
, 247 248 5652 5653 O
vincristine 249 260 5654 5665 B-treatment
, 260 261 5665 5666 O
chlorambucil 262 274 5667 5679 B-treatment
, 274 275 5679 5680 O
cytarabine 276 286 5681 5691 B-treatment
, 286 287 5691 5692 O
gemcitabine 288 299 5693 5704 B-treatment
, 299 300 5704 5705 O
platinum 301 309 5706 5714 B-treatment
drugs 310 315 5715 5720 I-treatment
, 315 316 5720 5721 O
etoposide 317 326 5722 5731 B-treatment
) 326 327 5731 5732 O

